Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumit Isharwal

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
BJU International|September 30, 2010
Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason scoreYing Huang, Sumit Isharwal, Alexander Haese, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 12, 2020
Differences in Patient-Reported Outcomes That Are Most Frequently Detected in Randomized Controlled Trials in Patients With Solid Tumors: A Pooled Analysis of 229 TrialsJohannes M Giesinger, Jane Blazeby, Neil K Aaronson, et al.
Cancer Biomarkers : Section a of Disease Markers|September 26, 2015
Evaluation of two mitochondrial DNA biomarkers for prostate cancer detectionSamantha Maragh, Robert W Veltri, Steven P Lund, et al.
Cancer Research|January 2, 2009
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancerRong Hu, Thomas A Dunn, Shuanzeng Wei, et al.
The Journal of Urology|August 21, 2012
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancerJeffrey J Tosoian, Stacy Loeb, Zhaoyong Feng, et al.
European Urology|June 7, 2017
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic TargetsEugene J Pietzak, Aditya Bagrodia, Eugene K Cha, et al.
European Urology Focus|August 14, 2017
Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial CarcinomaSumit Isharwal, François Audenet, Esther Drill, et al.
The Journal of Pathology|March 7, 2019
Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladderSumit Isharwal, Wenhuo Hu, Judy Sarungbam, et al.
Human Pathology|March 31, 2018
Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinomaSumit Isharwal, Hongying Huang, Gouri Nanjangud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2018
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial CarcinomaFrançois Audenet, Sumit Isharwal, Eugene K Cha, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
BJU International|September 30, 2010
Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason scoreYing Huang, Sumit Isharwal, Alexander Haese, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 12, 2020
Differences in Patient-Reported Outcomes That Are Most Frequently Detected in Randomized Controlled Trials in Patients With Solid Tumors: A Pooled Analysis of 229 TrialsJohannes M Giesinger, Jane Blazeby, Neil K Aaronson, et al.
Cancer Biomarkers : Section a of Disease Markers|September 26, 2015
Evaluation of two mitochondrial DNA biomarkers for prostate cancer detectionSamantha Maragh, Robert W Veltri, Steven P Lund, et al.
Cancer Research|January 2, 2009
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancerRong Hu, Thomas A Dunn, Shuanzeng Wei, et al.
The Journal of Urology|August 21, 2012
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancerJeffrey J Tosoian, Stacy Loeb, Zhaoyong Feng, et al.
European Urology|June 7, 2017
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic TargetsEugene J Pietzak, Aditya Bagrodia, Eugene K Cha, et al.
European Urology Focus|August 14, 2017
Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial CarcinomaSumit Isharwal, François Audenet, Esther Drill, et al.
The Journal of Pathology|March 7, 2019
Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladderSumit Isharwal, Wenhuo Hu, Judy Sarungbam, et al.
Human Pathology|March 31, 2018
Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinomaSumit Isharwal, Hongying Huang, Gouri Nanjangud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2018
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial CarcinomaFrançois Audenet, Sumit Isharwal, Eugene K Cha, et al.
Pageof 6